My Research Vision
The objective of my research is the understanding of the disease process and the intracellular signal transduction mechanisms and cellular stress responses that lead to cardiac contractile dysfunction and myocardial injury aligned to diabetes, heart failure and drug induced cardiotoxicity, with an aim to provide a rational basis for prevention or therapeutic intervention, including the involvement of biomarker identification. I have been instrumental in investigating the impact of mitochondrial function aligned to cardiovascular cellular stress responses, as evidenced by my publications. In addition I am currently in the process of exploiting the commercial aspect of my research and I have filed several priority patents to support the formation of the university spin-out company - InoCardia.
My research outputs in the cardiovascular area include over 41 peer-reviewed publications (full papers, book chapter and abstracts). My research was returned in the RAE UoA12 assessment within the Allied Health Professionals submission. I review grants for a variety of funding bodies including Wellcome Trust, MRC and BHF and prolific MSc and PhD examiners, as well being responsible for editing the British Society for Cardiovascular Research Journal Bulletin.
I have given invited talks about my research to both national and international academic audiences and within industry, and have given interviews on BBC radio about science-related issues. I have experience of establishing strong collaborative partnerships with basic science, clinical and industry colleagues at UHCW, Birmingham Children’s Hospital, UCL, Glostrup University Hospital, University of Cape Town, Covance and World Precision Instruments, to name but a few examples, in order to enable the translation of our teams pre-clinical cardiovascular research findings into a clinical and commercial setting. In order to progress research at Coventry University I am committed to concentrating on building and developing the academic and commercial research in the area of cardiovascular biology, supported by the world leading external collaborators from academia and industry.
- Maddock H.L., Mocanu, M.M., Baxter, G., Lawrence, C.L., Standen, N.B., and Yellon, D.M. (2001) 'Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide'. Circulation 103, 3111-3116.
- Hausenloy, D.J., Maddock, H., Baxter, G., and Yellon, D.M. (2002) 'Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?'. Cardiovascular Research 55, 534-543.
- Maddock, H., Mocanu, M.M., and Yellon, D.M. (2002) 'Adenosine A3 receptor activation protects the myocardium from reperfusion/reoxygenation injury'. American Journal of Physiology 283, 1307-1313.
- Maddock, H., Broadley, K.J., Bril, A., and Khandoudi, N. (2002) 'Effects of adenosine receptor agonists on guinea-pig isolated working hearts and the role of endothelium and NO'. Journal of Pharmacy and Pharmacology 54, 859-867.
- Bell, R.M., Maddock, H., and Yellon, D.M. (2003) 'The cardioprotective and mitochondrial depolarising properties of exogenous nitric oxide in mouse heart'. Cardiovascular Research 57 (2), 405-415.
- Maddock, H., Gardner, N.M., Khandoudi, N., Bril, A., and Broadley, K.J. (2003) 'Protection from myocardial stunning by ischaemia and hypoxia with the adenosine A(3) receptor agonist, IB-MECA'. European Journal of Pharmacology 477 (3), 235-245.
- Maddock, H., Siedlecka, S.M., and Yellon, D.M. (2004) 'Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide'. Cardiovascular Drugs and Therapy 18, 113-119.
- Hausenloy, D.J., Maddock, H.L., Baxter, G., and Yellon, D.M. (2012) 'Paradigm shifts in cardioprotection research – the importance of the MPTP as a therapeutic target'. Cardiovascular Research 96 (2), 160-164.
- Gharanei, M., Hussain, A., Janneh, O., and Maddock, H.L. (2013) 'Doxorubicin induced myocardial injury is exacerbated following ischaemic stress via opening of the mitochondrial permeability transition pore'. Toxicology and Applied Pharmacology 268 (2), 149-156.
- Sandhu, H., and Maddock H.L. (2014) 'Molecular basis of cancer therapy induced cardiotoxicity: Introducing microRNA biomarkers for early assessment of subclinical myocardial injury'. Clinical Science 126 (6), 377-400.